Research and development

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Q&A, Exercise, Patient, Pulmonary hypertension, Cardiovascular Research, Clinical trial, IP, Therapy, LINK, Research, Science, LEVEL, Public expenditure, Heart failure, Development, Tenax, Disease, KOL, TNX-102, First, Research and development, MPH, Cardiology, Conference, Patent, Doctor of Philosophy, Faculty, MBA, Levosimendan, THT, Feinberg School of Medicine, Pharmaceutical industry

We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.

Key Points: 
  • We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.
  • In February 2024, Tenax Therapeutics announced that the first patient had enrolled in the Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ).
  • LINK TO REGISTER
    Tenax Therapeutics reported cash and cash equivalents of $9.8 million as of December 31, 2023.
  • Tenax Therapeutics reported a net loss for 2023 of $7.7 million, compared to a net loss of $11.0 million in 2022.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Innodata

Retrieved on: 
Thursday, March 28, 2024
Research, Growth, Defendant, News, LLP, AI, Nature, Silicon, Goldengate, Research and development, Advertising, Wolfpack, Marketing, Court, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Innodata’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Wednesday, March 27, 2024
De novo, DFU, Diabetic foot ulcer, Certification, Burn, Government, Development, FY, MDAI, Patient, Research, History, Artificial intelligence, Classification, Sale, Standard of care, Human services, Research and development, Wound healing, Trial of the century, Clinical trial, ASPR, ISO, FDA, Administration, Food, Pharmaceutical industry

DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.

Key Points: 
  • DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
  • “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer.
  • “
    In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million.
  • All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Administration, EGFR, Mutation, Index, Colorectal cancer, Cetuximab, Central nervous system, Novartis, Webcast, Patient, GBM, CNS, Neoplasm, Acquisition, G&A, Insurance, BRAF, NRAS, MEK, CRC, Melanoma, ASCO, ID, MTD, Research and development, Probability, Data, FDA, Outsourcing, FTD, Pharmaceutical industry

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points: 
  • In addition, a strategic pipeline prioritization sharpened Erasca’s focus on existing programs that we believe have the highest probability of success for patients.
  • Research and Development (R&D) Expenses: R&D expenses were $24.8 million for the quarter ended December 31, 2023, compared to $29.4 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.1 million for the quarter ended December 31, 2023, compared to $8.7 million for the quarter ended December 31, 2022.
  • Erasca will hold a conference call and webcast on Thursday, March 28, 2024 at 8:30 am ET.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Research, Consultant, Administration, Patient, Breast, Prostate, Insurance, IND, Data collection, Investment, Interim, Therapy, Research and development, FDA, NK, Pharmaceutical industry

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $1.81 million compared to $2.94 million for the same quarter in 2022.
  • Other income net of other expenses, for the fourth quarter ended December 31, 2023 was $0.21 million compared to $0.19 million for the same quarter ended December 31, 2022.
  • Net Loss: The Company reported a net loss of $2.96 million for the fourth quarter ended December 31, 2023 compared to a loss of $5.58 million for the same quarter in 2022.

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, March 26, 2024
Research, Piz, Adenosine deaminase, Half-life, Patient, Alnylam Pharmaceuticals, AAT, ADAR, Mouse, RNA, Chord, N-Acetylgalactosamine, Hepatocyte, Investment, Customization, Protein, Therapy, Research and development, Administration, Liver, Vaccine

KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro’s platform called Oligonucleotide Promoted Editing of RNA (OPERA™).

Key Points: 
  • KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro’s platform called Oligonucleotide Promoted Editing of RNA (OPERA™).
  • Using CHORDs, Korro achieved greater than 50% editing using GalNAc conjugates with subcutaneous administration to the liver in a preclinical mouse model.
  • Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and short-term investments were $166.1 million as of December 31, 2023, compared to $55.2 million as of December 31, 2022.
  • Net Loss: Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Retrieved on: 
Tuesday, March 26, 2024
Research, Toxicity, Central nervous system, PIN, Administration, Immunotherapy, Emax, Science, Patient, AstraZeneca, Food and Drug Administration, Biomarker, G&A, Plaque, Chemistry, Therapy, Neurogranin, Safety, ABOS, Research and development, Plasma protein binding, Food, Pharmaceutical industry

We delivered the first Phase 1 results from an oligomer-targeted antibody for the treatment of early Alzheimer’s disease, which exceeded expectations.

Key Points: 
  • We delivered the first Phase 1 results from an oligomer-targeted antibody for the treatment of early Alzheimer’s disease, which exceeded expectations.
  • We also expect to initiate a subcutaneous bioavailability study in mid-2024, to extend the product profile and offer administration optionality for patients.
  • Dr. Doherty brings decades of neuroscience-focused research and clinical development expertise to Acumen, from discovery through drug approval.
  • Net loss for the year ended December 31, 2023 was $52.4 million, compared to a net loss of $42.9 million for the year ended December 31, 2022.

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
HOPE, Orchestra, Environment, CFO, Siemens Healthineers, Partnership, Patient, Knowledge, Medtronic, Senior, Marketing, Research and development, SAB, Division, Management

Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers.

Key Points: 
  • Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers.
  • Prior to joining Siemens Healthineers, he was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular, overseeing the company’s business in North America.
  • “It’s an honor to welcome Dave to the Orchestra BioMed Board where we expect to benefit from his wealth of experience in driving the adoption of transformational device therapies and procedural imaging modalities,” said David Hochman, chairman, chief executive officer and founder of Orchestra BioMed.
  • I look forward to contributing my perspective to help Orchestra BioMed realize the full potential of its cardiovascular pipeline, strategic partnerships and differentiated business model.”

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Administration, CSF1R, TREM2, MRI, Data analysis, PD, CSF, Magnetic resonance imaging, Patient, Biomarker, Microglia, Osteopontin, Fluid mechanics, IGNITE, Investment, Clinical trial, Pharmacokinetics, Interim, Research and development, Data, FDA, AFL, Pharmaceutical industry

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points: 
  • “Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
  • We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
  • Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
  • The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Innodata, Fox Factory, Lantronix, and Palo Alto Networks and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Research, Class Action, Growth, Palo Alto Networks, Intelligence, Federation, EPS, Internet of things, PANW, Defendant, Internet, News, Transport, AI, Nature, Complaint, Silicon, City, P.C, Goldengate, Research and development, Fox Factory, Wolfpack, Marketing, IOT

Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.

Key Points: 
  • Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.
  • On this news, the price of Innodata common stock declined by $3.74 per share, or approximately 30.5%, on February 15, 2024.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW